Please login to the form below

Not currently logged in
Email:
Password:

India passes clinical trials compensation law

Pharma sponsors will need to pay in cases of trial-related injuries and deaths

India has amended its clinical trials laws, adding new rules that will oblige pharma companies sponsoring trials to pay compensation in cases where volunteers suffer trial-related death or injury.

The Ministry of Health & Family Welfare ruling comes a month after the Supreme Court of India, based in New Delhi, criticised the country's government for poor regulation of clinical trials.

Compensation will be decided on a case-by-case basis, according to a local report in The Economic Times, and failure to pay up could see pharma firms and clinical research organisations (CROs) face suspension of trials and even a permanent ban on their activities.

However, the Indian Society of Clinical Research (ISCR) criticised sections of the new amendment on compensation, which they believe will have "a far-reaching impact on organisations and academic institutes, both Indian and multination".

The ISCR said: "The clauses stating that compensation needs to be paid for injury or death due to failure of investigational product to provide intended therapeutic effect and use of placebo in placebo controlled trials contradict the scientific base of a clinical trial."

The institute added: "It is ironical that the Ministry notification has come around the same time that the US FDA is holding a hearing to discuss with industry experts how a speedier pathway to approve drugs and biologics for serious and life-threatening conditions with unmet medical needs can be constructed."

7th February 2013

From: Research, Regulatory

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
HAVAS LYNX

Welcome to HAVAS LYNX, a leading global healthcare communications group....

Latest intelligence

ema1
The European Medicines Agency: PRIME’d for access?
Leela Barham examines the impact of the EMA's PRIME fast track system after two years...
How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...

Infographics